Entropy Neurodynamics Limited (ENP) - Total Assets
Based on the latest financial reports, Entropy Neurodynamics Limited (ENP) holds total assets worth AU$6.66 Million AUD (≈ $4.71 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Entropy Neurodynamics Limited net assets for net asset value and shareholders' equity analysis.
Entropy Neurodynamics Limited - Total Assets Trend (2018–2025)
This chart illustrates how Entropy Neurodynamics Limited's total assets have evolved over time, based on quarterly financial data.
Entropy Neurodynamics Limited - Asset Composition Analysis
Current Asset Composition (June 2025)
Entropy Neurodynamics Limited's total assets of AU$6.66 Million consist of 95.3% current assets and 4.7% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$3.03 Million | 45.4% |
| Accounts Receivable | AU$2.76 Million | 41.5% |
| Inventory | AU$0.00 | 0.0% |
| Property, Plant & Equipment | AU$114.66K | 1.7% |
| Intangible Assets | AU$195.49K | 2.9% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how Entropy Neurodynamics Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Entropy Neurodynamics Limited.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Entropy Neurodynamics Limited's current assets represent 95.3% of total assets in 2025, an increase from 36.6% in 2018.
- Cash Position: Cash and equivalents constituted 45.4% of total assets in 2025, up from 17.0% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, a decrease from 56.0% in 2018.
- Asset Diversification: The largest asset category is cash and equivalents at 45.4% of total assets.
Entropy Neurodynamics Limited Competitors by Total Assets
Key competitors of Entropy Neurodynamics Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Entropy Neurodynamics Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.08 | 3.63 | 4.40 |
| Quick Ratio | 9.08 | 3.63 | 4.40 |
| Cash Ratio | 4.33 | 2.75 | 0.00 |
| Working Capital | AU$5.65 Million | AU$5.13 Million | AU$3.14 Million |
Entropy Neurodynamics Limited - Advanced Valuation Insights
This section examines the relationship between Entropy Neurodynamics Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.10 |
| Latest Market Cap to Assets Ratio | 6.35 |
| Asset Growth Rate (YoY) | -10.6% |
| Total Assets | AU$6.66 Million |
| Market Capitalization | $42.34 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Entropy Neurodynamics Limited's assets at a significant premium (6.35x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Entropy Neurodynamics Limited's assets decreased by 10.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Entropy Neurodynamics Limited (2018–2025)
The table below shows the annual total assets of Entropy Neurodynamics Limited from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$6.66 Million ≈ $4.71 Million |
-10.60% |
| 2024-06-30 | AU$7.45 Million ≈ $5.27 Million |
+26.72% |
| 2023-06-30 | AU$5.88 Million ≈ $4.16 Million |
-56.80% |
| 2022-06-30 | AU$13.61 Million ≈ $9.63 Million |
-36.55% |
| 2021-06-30 | AU$21.46 Million ≈ $15.18 Million |
+227.96% |
| 2020-06-30 | AU$6.54 Million ≈ $4.63 Million |
+21.14% |
| 2019-06-30 | AU$5.40 Million ≈ $3.82 Million |
+1651.96% |
| 2018-06-30 | AU$308.26K ≈ $218.11K |
-- |
About Entropy Neurodynamics Limited
Entropy Neurodynamics Limited, a clinical-stage pharmaceutical development company, focuses on developing formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs in Australia, Canada, Switzerland, and the United States. The company's lead program candidate is TRP-8803, a formulation of IV-infused psilocin that completed Phase 2 … Read more